NCT04216888View on ClinicalTrials.gov

Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 26, 2019

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG

Ketamine Hydrochloride

Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device

Trial Locations (1)

10962

Nathan Kline Institute, Orangeburg

All Listed Sponsors
lead

Dan Iosifescu

OTHER

NCT04216888 - Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine | Biotech Hunter | Biotech Hunter